Tuesday, May 17, 2016

BRIEF-Navidea reports Q1 loss per share of $0.02

* Expects to begin grant-funded phase 1/2 evaluation of

lymphoseek - iv in kaposi's sarcoma patients in second half of

2016

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)